Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNAGEN: A Generative Adversarial Network-Based Model to Generate Synthetic RNA Sequences to Target Proteins.

Chembiochem : a European journal of chemical biology·2026
Same author

A cell atlas of the developing human outflow tract of the heart and its adult aortic valve derivatives.

eLife·2026
Same author

metaAPA: a tool for integration of PolyA site predictions from single-cell and spatial transcriptomics.

Bioinformatics advances·2026
Same author

A novel soil-derived Mycolicibacterium decreases anxiety-like defensive behavioral responses in association with decreases in biomarkers of neuroinflammation and hippocampal microglial priming in adult male rats.

Brain, behavior, and immunity·2026
Same author

Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study.

EClinicalMedicine·2026
Same author

Integration of unpaired and heterogeneous clinical flow cytometry data.

iScience·2026
Same journal

OmicsTransformer: Self-Supervised Masked Consistency and Uncertainty-Aware Fusion for Robust Multi-Omics Prediction.

Bioinformatics (Oxford, England)·2026
Same journal

Computational Tool Choice Impacts CRISPR Spacer-Proto spacer Detection.

Bioinformatics (Oxford, England)·2026
Same journal

ARISE: RNA-Anchored Shared-Edge Topology and Hierarchical Fusion for Spatial Multi-Omics Integration.

Bioinformatics (Oxford, England)·2026
Same journal

Interactive exploration of biobank-scale ancestral recombination graphs with Lorax.

Bioinformatics (Oxford, England)·2026
Same journal

PepMCP: A Graph-Based Membrane Contact Probability Predictor for Membrane-Lytic Antimicrobial Peptides.

Bioinformatics (Oxford, England)·2026
Same journal

ARGscape: A modular, interactive tool for manipulation of spatiotemporal ancestral recombination graphs.

Bioinformatics (Oxford, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

DeepSynBa: Actionable Drug Combination Prediction with Complete Dose-Response Profiles.

Halil Ibrahim Kuru1, Haoting Zhang2,3, Magnus Rattray4

  • 1Department of Computer Engineering, Bilkent University, Ankara, Turkey.

Bioinformatics (Oxford, England)
|June 21, 2026
PubMed
Summary
This summary is machine-generated.

DeepSynBa predicts the full dose-response matrix for cancer drug combinations, improving accuracy over single synergy scores. This actionable model aids in selecting optimal dosages to enhance efficacy and reduce toxicity.

Keywords:
actionable modellingdeep learningdose-response predictiondrug combinationsdrug synergy

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Related Experiment Videos

Last Updated: Jun 23, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

Area of Science:

  • Computational biology
  • Pharmacology
  • Bioinformatics

Background:

  • Cancer monotherapies often show limited efficacy, necessitating combination therapies.
  • Predicting drug combination responses is complex due to numerous combinations and context-specific profiles.
  • Current models oversimplify drug responses, leading to uncertainty and limited actionability.

Purpose of the Study:

  • To introduce DeepSynBa, a novel computational model for predicting drug combination responses.
  • To move beyond aggregated synergy scores and predict the complete dose-response matrix.
  • To provide an actionable tool for optimizing drug combination therapies.

Main Methods:

  • DeepSynBa predicts dose-response matrix parameters as an intermediate step.
  • The model was evaluated on the NCI-ALMANAC and O'Neil datasets.
  • Performance was assessed across novel drug combinations, cell lines, drugs, and tissue types.

Main Results:

  • DeepSynBa outperforms state-of-the-art methods in dose-response matrix prediction.
  • The model demonstrates reliable synergy score predictions.
  • DeepSynBa accurately predicts responses for untested combinations across various dosages.

Conclusions:

  • DeepSynBa offers a powerful, actionable approach to drug combination research.
  • The model separates efficacy from potency, guiding dosage selection for optimal outcomes and reduced toxicity.
  • DeepSynBa advances the field beyond the limitations of current aggregated synergy score models.